CHAIRMAN. - Hernán Cortés-Funes, Hospital Universitario 12 de Octubre, Instituto de Investigación i+12, Madrid, Spain FACULTY

Transcription

1

2 CHAIRMAN - Hernán Cortés-Funes, Hospital Universitario 12 de Octubre, Instituto de Investigación i+12, Madrid, Spain FACULTY - Alex A. Adjei, Roswell Park Cancer Institute, Buffalo, New York, USA - Emilio Alba, Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain - Joan Albanell, Hospital del Mar, Barcelona, Spain - Richard Baird, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK - Udai Banerji, The Institute of Cancer Research, Sutton, London, UK - Hilary Calvert, University of Newcastle, Newcastle, UK - Carlos Camps, Hospital General Universitario, Valencia, Spain - Hernán Cortés-Funes, Hospital Universitario 12 de Octubre, Instituto de Investigación i+12, Madrid, Spain - José Manuel Cuezva, Centro Superior de Investigaciones Científicas, CSIC, Madrid, Spain - Johann de Bono, The Institute of Cancer Research, The Royal Marsden, London, UK - Eduardo Díaz Rubio, Hospital Universitario Clínico San Carlos, Madrid, Spain - Federico Gago, Universidad de Alcalá, Alcalá de Henares, Madrid, Spain - Carlos Galmarini, Pharmamar, Madrid, Spain - Milagros González-Rivera, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain - Axel Hanauske, Eli Lilly and Company, Frankfurt, Germany - Yolanda Jerez, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain - José Antonio López Martín, Hospital Universitario 12 de Octubre, Instituto de Investigación i+12, Madrid, Spain - Santos Mañés, Centro Superior de Investigaciones Científicas, CSIC, Madrid, Spain - Ignacio Melero, Clínica Universitaria de Navarra, Pamplona, Spain - Atanasio Pandiella, CSIC Salamanca, Salamanca, Spain - Estela Paz, Hospital Universitario 12 de Octubre, Instituto de Investigación i+12, Madrid, Spain - Luis Paz-Ares, Hospital Virgen del Rocío, Sevilla, Spain - Sandra Peiró, Fundación Institut Mar d'investigacions Médiques (IMIM), Barcelona, Spain - César Picó, Bavarian Nordic ImmunoTherapeutics, Madrid, Spain - Santiago Ponce, Hospital Universitario 12 de Octubre, Instituto de Investigación i+12, Madrid, Spain - Manuel Ramírez, Hospital Infantil Universitario Niño Jesús, Madrid, Spain - Eric Raymond, Swiss Cancer Center-CHUV, Lausanne, Switzerland - José R. Regueiro, Universidad Complutense de Madrid, Madrid, Spain - Jordi Rodón, Hospital General Universitario Vall d'hebron, Barcelona, Spain - Rafael Rosell, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain - Claudia Rossig, Universität Münster, Muenster, Germany - Jan Schellens, Nederlands Kanker Instituut, Amsterdam, The Netherlands - Andreas Schröder, CureVac GmbH, Frankfurt, Germany - Charles Swanton, London Research Institute, London, UK - Anthony Tolcher, South Texas Accelerated Research Therapeutics, LLC-START, San Antonio, Texas, USA *To be confirmed

3 TARGETED THERAPEUTICS IN CANCER: RECAPITULATION AND APPRAISAL OF 15 YEARS OF CLINICAL RESEARCH. INTRODUCING IMMUNO-ONCOLOGY WEDNESDAY 2 JULY, pm Welcome and Introduction H. Cortés-Funes (Madrid, Spain) 4.15 pm Opening Lecture: My journey and perspectives on clinical drug development H. Calvert (Newcastle, UK) 4.45 pm Session 1. Round Table Controversies in methods for early clinical anticancer research Chairmen: J. de Bono (London, UK), A. Tolcher (San Antonio, TX, USA) 4.45 pm Have novel endpoints added any value in Phase 1 clinical trials in Oncology? A. Tolcher (San Antonio, TX, USA) 5.00 pm Do new dose escalation methods really impact in the efficiency of early clinical development? J. Schellens (Amsterdam, The Netherlands) 5.15 pm Molecular selection of patients in early clinical development: do the advantages overweigh the risks? J. Rodón (Barcelona, Spain) 5.30 pm Monitoring biomarkers during early clinical research expensive futility? E. Raymond (Lausanne, Switzerland) 5.45 pm A review of the utility of Phase 0 trials in Oncology A. A. Adjei (Buffalo, NY, USA) 6.00 pm Are we missing something critical in the design and development of drug combinations? J. de Bono (London, UK) 6.15 pm Table discussion 6.45 pm Adjourn

4 THURSDAY 3 JULY, am Session 2. Light and shadows in anticancer pathway modulations (Part 1) Chairmen: C. Camps (Valencia, Spain), A. Pandiella (Salamanca, Spain) 8.30 am HER inhibition- should we have additional expectations? New TKIs targeting EGFR R. Rosell (Barcelona, Spain) New monoclonal antibodies targeting HER family J. Albanell (Barcelona, Spain) 9.30 am PI3K / AKT inhibition what s the buzz? Opportunities for PI3K inhibition data and mechanisms of resistance R. Baird (Cambridge, UK) Rationale for developing PI3K pathway inhibitors in combination U. Banerji (London, UK) am Coffee Break Poster Session am Session 3. Light and shadows in anticancer pathway modulations (Part 2) Chairmen: J. Albanell (Barcelona, Spain), S. Ponce (Madrid, Spain) am IGF-1R inhibition: any basis for not giving up? A. Tolcher (San Antonio, TX, USA) am Cell metabolism as a source of new targets for anticancer research The metabolic signature of cancer cells J. M. Cuezva (Madrid, Spain) Targeting hypoxia in cancer cells J. A. López Martín (Madrid, Spain) pm The development of TGFb inhibitors in anticancer research E. Raymond (Lausanne, Switzerland) 1.15 pm LUNCH SYMPOSIUM Genetic advances in the management of early stage breast cancer 1.15 pm Lecture Tumor molecular heterogeneity and evolution C. Swanton (London, UK)

5 1.45 pm Contribution of the new generation genomic test in clinical practice: merits of Prosigna for Early Breast Cancer decision making Y. Jerez (Madrid, Spain) 2.00 pm Interest and value of Prosigna as a decentralized test, our laboratory experience M. González-Rivera (Madrid, Spain) 2.15 pm Discussion and Chairman Conclusion 3.00 pm Session 4. Light and shadows in anticancer pathway modulations (Part 3) Chairmen: R. Baird (Cambridge, UK), E. Díaz-Rubio (Madrid, Spain) 3.00 pm A comprehensive review on the development of PARP inhibitors H. Calvert (London, UK) 3.30 pm HSP 90 inhibitors: any new (non-toxic) compound in development? U. Banerji (London, UK) 4.00 pm The development of c-met inhibitors in cancer A. Adjei (Buffalo, NY, USA) 4.30 pm Strategies for reversal of tumor unresponsiveness J. Schellens (Amsterdam, The Netherlands) 5.00 pm Coffee Break Poster Session 5.30 pm Session 5. Light and shadows in anticancer pathway modulations (Part 4) Chairmen: E. Alba (Malaga, Spain), F. Gago (Alcalá de Henares, Spain) 5.30 pm New monoclonal antibodies targeting angiogenesis A. Hanauske (Frankfurt, Germany) 6.00 pm Next generation FGFR inhibitors in cancer research L. Paz-Ares (Sevilla, Spain) 6.30 pm What s going on with agents targeting epigenetics? S. Peiró (Barcelona, Spain) 7.00 pm Adjourn

6 FRIDAY 4 JULY, am Session 6. Introducing Immuno-Oncology (Part 1) Chairmen: S. Mañés (Madrid, Spain), J. R. Regueiro (Madrid, Spain) 8.30 am Immunomodulation: From CTLA-4 blockade to combinatorial immunotherapy I. Melero (Pamplona, Spain) 9.00 am PD-1 pathway modulation in cancer TBD 9.30 am Oncolytic viruses, deliverying what they promised? M. Ramírez (Madrid, Spain) am Coffee Break Poster Session am Session 7. Introducing Immuno-Oncology (Part 2) Chairmen: I. Melero (Pamplona, Spain), E. Paz (Madrid, Spain) am Active immunotherapy, poxvirus-based vaccines C. Picó (Madrid, Spain) am The development of self-adjuvanted mrna vaccines in cancer A. Schröder (Frankfurt, Germany) am CAR (Chimeric Antigen Receptor) T cells in cancer therapy C. Rossig (Muenster, Germany) pm Effects of marine-derived anticancer-compounds on the immune system C. Galmarini (Madrid, Spain) pm Closing Remarks H. Cortés-Funes (Madrid, Spain), J. A. López Martín (Madrid, Spain) pm Adjourn

7

8 VENUE Hotel H10 Andalucía Plaza Urb. Nueva Andalucía Puerto Banús, Marbella Málaga, Spain CONFERENCE SECRETARIAT BN&Co. Congress and Event Management Paseo de la Castellana, 179. Entreplanta Madrid - Spain Tel: Fax: m.e.fernandez@bnyco.com WEBSITE LANGUAGE The official language of the Conference is English. There will be no simultaneous interpretation. CREDITS This Conference is accredited by the European Society of Medical Oncology Continuing Education for its Medical Oncology Recertification Approval (ESMO/MORA) Program with 15 ESMO-MORA Category 1 points. POSTERS Posters will be visited during Coffee Breaks. WEATHER The weather in Marbella in July is hot and the days are shiny. The day temperature can average between 28º and 33º C. CLOTHING Dress will be casual for all Conference events. INSURANCE The organisers will not be responsible for individual, medical, travel or personal insurance. Participants are advised to take out their own personal insurance policies.

9 NO SMOKING Smoking will be forbidden in all Conference areas. MOBILE PHONES Mobile phones must be disconnected during all the sessions. REGISTRATION Fees (21% VAT included) Registration Fees After ESMO/EORTC Members 375 Non Members 460 Physicians in Training Taxes included. - Physicians in training must present a document signed by the Head of Department. Payment All payments must be made in Euro or credit cards, such as Eurocard, Master Card or Visa. Personal, company or Eurocheques are not accepted.

10 Sponsored by: